Claudin 18.2 Assay Portfolio Service
With unrivaled expertise and experience in immune-oncology discovery and development, Creative Biolabs is confident in providing an integrated solution for Claudin 18.2 assay services to best suit your program requirements.
Tumor Target Claudin 18.2
Claudin-18, also known as CLDN18, is a member of the claudin family, which are crucial components of the tight junction protein family mediating the flow of molecules between cell layers. CLDN18 has two isoforms, CLDN18.1 and Claudin 18.2. CLDN18.1 is selectively expressed in normal lung cells. While CLDN18.2 is expressed in differentiated gastric parietal cells and retained in malignant transformation of gastric cancer. Claudin18.2 shares the common structure of Claudin proteins, consisting of four transmembrane domains (Fig.1), two extracellular loops (ECL1, ECL2) and the intracellular NH2, COOH ends.
Fig.1 Model of claudin protein. (Günzel, 2013)
Claudin 18.2-Targeted Therapies
Claudin protein plays an important role in tumor invasion and metastasis, and its aberrant expression is found in various epithelial tumors. Ectopic activation of CLDN18.2 has been observed in gastric cancer and its metastatic foci, as well as in pancreatic, ovarian, esophageal and lung cancers.
Based on Claudin18.2 as a tissue-restricted tumor marker, it is an ideal target for the development of therapeutic strategies for various types of epithelial tumors. The novel antibody IMAB362 (zolbetuximab/ claudiximab) is highly specific to CLDN18.2 and illustrated the significant efficacy and safety profile in several tumors, including advanced gastric, pancreatic, non-small-cell lung cancers. Moreover, CLDN18.2-targeted ADCs, CAR-T therapies have been actively studied and shown encouraging results.
Fig.2 Claudin 18.2-targeted therapies.
Our Claudin 18.2 Assay Portfolio Services
Equipped with state-of-the-art facilities, Creative Biolabs has robustly developed tumor marker assay platforms and provides high-quality Claudin 18.2 assay portfolio services to help our clients meet their program needs. We are committed to designing a comprehensive research assay portfolio, covering the initial target validation to the later preclinical analysis to accelerate the research process.
For more details of our Claudin 18.2 assay portfolio services, please don’t hesitate to contact us for more information.
References
-
Günzel, D.; Yu, A.S. Claudins and the modulation of tight junction permeability. Physiological reviews. 2013, 93(2): 525-69.
-
Niu, Q.; et al. Future of targeted therapy for gastrointestinal cancer: Claudin 18.2. Oncology and Translational Medicine. 2021, 7(3): 102-107.
For Research Use Only | Not For Clinical Use
Download our brochure